Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_000548.5(TSC2):c.948G>A(p.Pro316=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000688 in 1,607,610 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. P316P) has been classified as Likely benign.
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 16-2058846-G-A is Benign according to our data. Variant chr16-2058846-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 49395.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-2058846-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-2.13 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00343 (523/152310) while in subpopulation AFR AF= 0.0121 (502/41568). AF 95% confidence interval is 0.0112. There are 3 homozygotes in gnomad4. There are 236 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Nov 28, 2022
- -
Likely benign, criteria provided, single submitter
not provided
Breakthrough Genomics, Breakthrough Genomics
-
- -
Benign, criteria provided, single submitter
clinical testing
CeGaT Center for Human Genetics Tuebingen
May 01, 2023
TSC2: BP4, BP7, BS1, BS2 -
Benign, criteria provided, single submitter
clinical testing
Athena Diagnostics
Nov 21, 2018
- -
not specified Benign:3
Benign, criteria provided, single submitter
clinical testing
GeneDx
Mar 01, 2013
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, criteria provided, single submitter
clinical testing
PreventionGenetics, part of Exact Sciences
-
- -
Benign, criteria provided, single submitter
clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Feb 21, 2013
Pro316Pro in exon 10 of TSC2: This variant is not expected to have clinical sign ificance because it does not alter an amino acid residue and is not located with in the splice consensus sequence. It has been identified in 1.3% (56/4392) of Af rican American chromosomes from a broad population by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS; dbSNP rs45517141). -
Tuberous sclerosis 2 Benign:3
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Nov 07, 2021
- -
Benign, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Feb 01, 2024
- -
Benign, criteria provided, single submitter
clinical testing
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Jul 07, 2023
- -
Hereditary cancer-predisposing syndrome Benign:2
Benign, criteria provided, single submitter
curation
Sema4, Sema4
Mar 23, 2020
- -
Likely benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Jan 01, 2015
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Tuberous sclerosis syndrome Benign:1Other:1
not provided, no classification provided
curation
Tuberous sclerosis database (TSC2)
-
- -
Benign, criteria provided, single submitter
clinical testing
All of Us Research Program, National Institutes of Health
Feb 05, 2024
- -
Lymphangiomyomatosis;C1846385:Isolated focal cortical dysplasia type II;C1860707:Tuberous sclerosis 2 Benign:1
Likely benign, criteria provided, single submitter